Drugs.com Clinical Trial ResultsOriginal article
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
RegulatorySAB-142Positive
AI Analysis
Summary
SAB Biotherapeutics received FDA Fast Track designation for SAB-142, a fully human anti-thymocyte immunoglobulin in development for Type 1 Diabetes and other autoimmune diseases. Fast Track status expedites the development and review process for this Stage 3 candidate.
Clinical Trial Data
Phase
Stage 3
Outcome Details
Fast Track designation received
Importance:7/10
Sentiment:
0.70
FDA Fast TrackType 1 DiabetesAutoimmune DiseasehATGClinical Stage
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 13, 2026 10:10 PM